Wednesday, February 23, 2022, at 3:00-4:00 pm ET (12:00-1:00 pm PT)
Speaker: Kimberly B. Shepard, Ph.D. – Lonza, Bend, OR
Title: “Local Treatment of Non-Small-Cell Lung Cancer by Dry Powder Inhaler: A Spray Dried Bevacizumab Formulation”

Local treatment of lung cancer by the inhalation route has the potential to improve patient compliance, reduce treatment costs and even reduce dose. Dry powder inhalers (DPIs) are the most popular device for lung delivery in a patient-friendly, shelf-stable package. Spray drying is used to enable particle engineering of delicate molecules, such as monoclonal antibodies (mAbs), for use in DPIs. Here we present a case study using an inhaled formulation of bevacizumab, a mAb VEGF-inhibitor formulated via spray drying. It was tested in a pre-clinical rat model of NSCLC and found to reduce tumor burden as effectively as injections.

Speaker Bio
Kim Shepard is a Principal Engineer at Lonza’s Bend, OR site, where she has worked for 7 years. Her work in the R&D group has focused on developing new processes, formulations, and technologies in the areas of inhalation particle engineering and bioavailability enhancement for oral delivery, focusing particularly on spray drying. She received her Ph.D. in chemical engineering from Princeton University, studying polymer physics and amorphous materials. Kim also received a B.E. and M.E. in chemical engineering from Stevens Institute of Technology.

Registration: HTTP://aaps-badg.org/event-registration

Event Information

Event Topic:
Local Treatment of Non-Small-Cell Lung Cancer by Dry Powder Inhaler: A Spray Dried Bevacizumab Formulation

Event Description:

Date/Time:
Date(s) - 02/23/22
12:00 pm - 1:00 pm

Event Location:
Other:

Event Details

Event Type